Ads
related to: latest developments in schizophrenia and addiction counselingconsumerhorse.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
RECOVER-2 is a confirmatory 4-week, randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of 450 acute schizophrenia patients, where patients will receive brilaroxazine 30 mg, 50 mg, or placebo once daily. Completion is expected in Q2 2025 and brilaroxazine FDA new drug application (NDA) submission is expected in Q3 ...
N o new treatments for schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ...
Iclepertin (developmental code name BI 425809) is an investigational nootropic to enhance the cognition and functional capacity in schizophrenia developed by Boehringer Ingelheim. As of May 2020, it is in phase III of clinical trial under the code name CONNEX-3. [ 1 ]
Soteria emerged as a response to former psychiatric patients who said that they needed "love and food and understanding, not drugs", [8] by providing an alternative centered on development, learning, and growth, [7]: 113 and by comparing its results to those of the traditional model.
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.
Ads
related to: latest developments in schizophrenia and addiction counselingconsumerhorse.com has been visited by 100K+ users in the past month